pfizer news - Search News

RSV, Pfizer

Pfizer gets a leg up in RSV as FDA clears jab for all adults

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.

Reuters on MSN · 14h

US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.

The Wall Street Journal on MSN · 14h

Pfizer Receives FDA Approval for RSV Vaccine

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,

Seeking Alpha on MSN · 13h

Pfizer RSV vaccine Abrysvo gains expanded indication

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,

Pfizer, Starboard

Reuters · 20h

Starboard Value CEO says Pfizer's board should hold management accountable

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance, particularly for its record for producing profitable new drugs.

FiercePharma · 21h

UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management,

Business Insider · 16h

Starboard urges Pfizer board to ‘hold management accountable’, FT reports

Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable

21h

What activist hedge fund Starboard wants from Pfizer

Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...

8hon MSN

Transcript: An activist tried to take on Pfizer. Then things got messy

This is an audio transcript of the Behind the Money podcast episode: ‘An activist tried to take on Pfizer. Then things got ...

pharmaphorum5h

Starboard spells out its concerns with Pfizer's direction

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

18h

Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...

FiercePharma14h

Pfizer lays off 75 more workers in North Carolina in wake of late-stage DMD trial fail

Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

STAT22h

Pharmalittle: We’re reading about a probe of Pfizer and Lilly telehealth, pharma exec donations, and more

Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...

BioPharma Dive19h

Starboard makes case for change at Pfizer, citing research, M&A missteps

The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.

21hon MSN

An Activist Makes the Case Against Pfizer. CEO Bourla is in His Sights

Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

RSV, Pfizer

Pfizer, Starboard

Related topics